ArticleTranslational vision science & technology2025
Effect of Periplaneta americana Extract on Corneal Fibrosis and Epithelial Healing After Rabbit Lamellar Keratectomy.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate Periplaneta americana extract (PAE) effects on corneal epithelial healing and fibrosis after superficial lamellar keratectomy (SLK) in rabbits. Methods: SLK was performed on the right eyes of 48 New Zealand White rabbits, randomized into three treatment groups (n = 16/group): normal saline (NS), Tobradex eye drops (TE), and PAE group. Corneal opacity and epithelial defect area were quantified using slit-lamp imaging at postoperative days 3, 7, 14, and 28 (D3, D7, D14, and D28) and scored via the grading system. We performed histopathological analysis to visualize tissue structure and immunohistochemistry (IHC) localize and quantify TGF-β1 protein in corneal tissues. Results: Significant intergroup differences in corneal epithelial defect area and opacity were observed on D3 and D7 (all P < 0.05). The TE group exhibited the largest epithelial defects but mildest corneal opacity, whereas the PAE group demonstrated the smallest epithelial defects and significantly reduced opacity compared to the NS group (P < 0.05). Time-dependent variations in epithelial defect area were noted across all groups (P < 0.05). The NS and TE groups displayed progressive corneal opacity increases, whereas the opacity of the PAE group peaked at D7 before declining. Histological analysis revealed epithelial detachment, stromal edema, and inflammatory infiltration in all groups, with the TE group showing milder inflammation. TGF-β1 expression levels initially increased followed by a decline in the NS and PAE groups, in contrast to the inverse trend of the TE group. No statistically significant differences in late-phase corneal opacity or TGF-β1 levels were observed between groups (all P > 0.05). Conclusions: During the early phase after SLK, PAE accelerated corneal tissue regeneration, inhibited corneal scarring, and partially restored corneal clarity. This biphasic regulatory effect may be attributed to promoting TGF-β1 expression in the early stage, followed by its inhibition in the later stages. Translational Relevance: PAE modulates TGF-β1 to balance corneal healing and fibrosis as a novel topical corticosteroid alternative, warranting human trials for its dual-phase healing/scarring action.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.